been shown to predict future cardiovascular events in patients with or without cardiovascular diseases. 14, 15 There is a growing body of evidence, ranging from the results of in vitro experiments to pathological analysis to epidemiological clinical studies, indicating that atherosclerosis is intrinsically an inflammatory disease. [16] [17] [18] Inflammatory reactions within the atherosclerotic lesions have been shown to reduce nitric oxide production and its bioavailability. 19 Furthermore, inflammatory biomarkers such as C-reactive protein (CRP) are positively associated with endothelial dysfunction in humans. 20, 21 These observations suggest that vascular inflammation might contribute to endothelial dysfunction. However, the direct involvement of vascular inflammation in endothelial dysfunction in humans remains unclear because of the lack of diagnostic modality to noninvasively evaluate vascular inflammation noninvasively in vivo. We, along with other investigations, have recently found that [ 18 F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) is capable of identifying and quantifying vascular inflammation within the atherosclerosis in humans. [22] [23] [24] [25] In this study, we examined whether vascular inflammation assessed by FDG-PET imaging of carotid arteries was independently associated with endothelial dysfunction evaluated by FMD of the brachial artery in 145 subjects. We further investigated whether absolute changes from baseline of %FMD after antihypertensive treatment for 6 months (∆%FMD) were correlated with those of target:background ratio (TBR) in 33 drug-naive essential hypertensive patients among the enrolled subjects.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. Table 1 shows the clinical characteristics of subjects. Twentyseven of 145 (18.6%) patients received statins, and 26 of 145 (17.9%) patients received antihypertensive agents without statins. The mean age was 61.8±9.5 years (range, 37-83), and there were 95 men (65.5%). There were 49 subjects without carotid atherosclerotic plaques (maximum carotid artery IMT<1.1 mm) and 96 with carotid plaques (maximum carotid artery IMT≥1.1 mm). The vessel diameter at baseline and at maximal dilation during reactive hyperemia was 3.98±0.63 and 4.20±0.65 mm, respectively. Mean and median (interquartile range) percent change in vasodilation (percent change over the baseline values; %FMD) was 5.78±2.06% and 5.52% (4.48%-6.91%), respectively. Nineteen patients had prevalent type 2 diabetes mellitus, in whom 13 patients (68.4%) received oral hypoglycemic agents. Ninety-six patients had essential hypertension. Of these, 36 patients (37.5%) received antihypertensive drugs such as diuretics, β-blockers, calciumchannel blockers, angiotensin-converting enzyme inhibitors, and angiotensin II type 1 receptor blockers. Twenty-six of 145 (17.9%) patients received statins. Figure 1 shows representative images of FDG-PET of 2 cases; one is the case with low %FMD level ( Figure 1A , left, and 1B, top), and the other with high %FMD level ( Figure 1A , right, and 1B, bottom). Note intense FDG uptake in the carotid arteries of low %FMD case. Table 2) .
Results

Clinical Characteristics and FDG-PET/Computed Tomographic Image of Subjects in the Study Design 1
Association Between Endothelial Function and Vascular Inflammation
Both endothelial dysfunction and arterial inflammation are well known to associate substantially with atherosclerosis. 18 We further assessed the relationship between %FMD and TBR values in the subgroup of individuals without carotid atherosclerotic plaques. Mean %FMD in individuals without atherosclerosis was significantly higher than those with atherosclerosis (6.26±2.20% versus 5.78±2.06%; P=0.045), whereas mean TBR was comparable between the 2 groups (1.47±0. 23 
Antihypertensive Treatment Effects on %FMD
Twenty-seven of 33 (81.8%) patients achieved the target blood pressure (<140/90 mm Hg). Four of 33 (12.1%) patients received statin therapy. Table 3 shows the clinical variables of 33 patients at baseline and after 6-month antihypertensive therapy. Coregistration of FDG-PET and computed tomographic images revealed that FDG was taken up into the carotid arteries, which was significantly suppressed by antihypertensive therapy ( Figure 2 ). As shown in Table 3 and Figure 3 , antihypertensive treatment significantly reduced systolic, diastolic, and mean blood pressures and decreased hsCRP and carotid artery TBR levels, whereas it increased %FMD and adiponectin values. There were no significant differences of anthropometric and metabolic parameters except high-density lipoprotein-cholesterol levels before and after the treatment for hypertension. ∆TBR was inversely and independently correlated with ∆%FMD in 33 patients with essential hypertension (r=−0.558; P<0.001; Table 4 ). No treatment-related serious adverse effects were observed in the present study. When we analyzed the class effect of antihypertensive agents, although there was no significant difference of changes in %FMD between 17 olmesartan-and 16 amlodipine-treated patients (1.00±0.21% versus 0.58±0.16% for Δ%FMD; P=0.141), TBR values were more decreased in patients who received olmesartan than those who received amlodipine (−0.13±0.04 versus −0.02±0.03 for ΔTBR; P=0.016). Moreover, although only 4 of 33 (12.1%) patients received statin therapy, it was not associated with either change in TBR (P=0.495) or %FMD values (P=0.061).
Antihypertensive therapy for 6 months also did not significantly affect renal function; it was changed from 77.7±15.5 to 79.4±15.5 L/min (P=0.394). Changes in renal function by antihypertensive therapy were not correlated with those in hsCRP (P=0.348), adiponectin (P=0.920), %FMD (P=0.187), or TBR values (P=0.354).
Discussion
The major findings of our study are as follows: (1) age, male sex, low-density lipoprotein-cholesterol, and vascular inflammation evaluated by TBR in the FDG-PET were independently associated with endothelial dysfunction, and (2) reduction in vascular inflammation was a sole independent associate of improvement of endothelial function after antihypertensive therapy. The present study suggests that vascular inflammation might be associated with endothelial dysfunction in humans. 
Endothelial Dysfunction and Inflammation
Many clinical studies have reported that endothelial function evaluated by FMD is impaired in patients with classical cardiovascular risk factors such as central obesity, diabetes mellitus, hypertension, and dyslipidemia. [5] [6] [7] [8] [9] [10] [11] [12] Furthermore, subclinical inflammation detected by elevation of hsCRP 20, 21 and the presence of chronic systemic infection 26 are also associated with endothelial dysfunction. In addition, we have found that vascular inflammation defined by FDG-PET is associated with the metabolic syndrome, 25 carotid thickness, and hsCRP, 25 suggesting the involvement of vascular inflammation in endothelial dysfunction. However, it remains unclear whether vascular inflammation could be independently associated with endothelial dysfunction in humans. We found here that vascular inflammation of carotid arteries defined by FDG-PET was associated with decreased %FMD, which was independent of classical coronary risk factors except age, HbA1c, and low-density lipoprotein-cholesterol. Moreover, ∆TBR was inversely correlated with ∆%FMD in essential hypertensive patients after 6-month therapy. These results suggest that vascular inflammation may play a role in endothelial dysfunction, thereby being one of the initial triggers of human atherosclerosis. 
Endothelial Dysfunction and Glycemic State
Although the study design 1 included only 19 type 2 diabetic patients and mean values of HbA1c and FPG were within the normal ranges, HbA1c values were significantly correlated with decreased %FMD (Table 2) . We, along with others, have previously reported that serum levels of advanced glycation end products, which are formed via nonenzymatic glycation of proteins, are inversely associated with FMD in both diabetic patients and subjects who underwent coronary risk-screening examinations. 27, 28 Therefore, even if HbA1c, a ketoamine and one of the intermediates of advanced glycation end products, was within a normal range, it may be a biomarker that reflects cumulative glycemic exposure, which may cause endothelial dysfunction.
In the present study, maximum carotid artery IMT, a predictor for future cardiovascular events, 29 was not correlated with endothelial dysfunction. Vascular inflammation could precede the morphological changes in carotid arteries, and that FDG-PET might be a more useful tool for detecting early phase of atherosclerosis. In subjects without carotid atherosclerotic plaques, besides carotid artery TBR, age was independently correlated with decreased %FMD. It was contrast to the case of patients with carotid atherosclerotic plaques; in these individuals, TBR was a sole and independent correlate of decreased %FMD (data not shown). These observations suggest that age may exert unfavorable effects on endothelial function, especially in patients without carotid atherosclerotic plaques.
Interventional Analysis
In the study design 1, 96 of 145 (66.2%) subjects had hypertension, which was the most common coronary risk factor observed in our cases. Therefore, we next examined whether ∆TBR was independently correlated with ∆%FMD in 33 essential hypertensive patients when they were treated with blood pressure-lowering agents for 6 months. In the study design 2, antihypertensive therapy significantly improved endothelial function and suppressed vascular inflammation, which were accompanied by the increase in adiponectin and the decrease in hsCRP levels (Table 3 ; Figure 3 ). Multiple stepwise regression analysis demonstrated that reduction of carotid artery TBR, but not blood pressure or hsCRP levels, was a sole independent predictor of improvement of %FMD after 6-month treatment ( Table 4 ). These observations further support the concept that vascular inflammation, rather than systemic inflammation or blood pressure, could contribute to endothelial dysfunction in humans. Because systolic blood pressure was not correlated with decreased %FMD (Table 2) , blood pressure-lowering agents may improve endothelial function partly via the direct anti-inflammatory effects on vessels. Furthermore, although several papers have shown the correlation between adiponectin levels and %FMD in high-risk patients or healthy young adults, 30, 31 baseline adiponectin levels and ∆adiponectin were not correlated with %FMD and ∆%FMD, respectively ( Table 2 ; Table 4 ). Antihypertensive treatment effects on %FMD may be independent of adiponectin.
Methodological Considerations
Because of a limited spatial resolution of the PET imaging, FDG activity in the carotid artery may be contaminated by that of blood pool in the target vessel. To address the issue, in this study, we obtained the PET imaging 2 hours after the FDG injection because delayed phase image could allow sufficient FDG accumulation in the arterial wall and to permit blood levels of FDG to become more reduced by decay and washout compared with the image obtained 1 hour after FDG administration, which is commonly used for oncology PET. 32, 33 Furthermore, TBR calculated as arterial standardized uptake value (SUV) score divided by venous blood SUV is generally used as an index of a quantitative parameter of vascular inflammation. 23, [32] [33] [34] [35] [36] Indeed, Tawakol et al 23 reported that TBR values in the carotid arteries were closely correlated with accumulation of CD68-positive macrophages in the corresponding histological sections of patients with severe carotid stenoses (r=0.85; P<0.001). Carotid TBR values were higher in patients with high-risk morphological features of atherosclerotic plaques, such as echolucent plaques, positive remodeling, luminal irregularity, and low attenuation in computed tomographic, than those without. 34, 35 In addition, carotid artery TBR has been shown to strongly predict subsequent cardiovascular disease in patients with no previous history of cardiovascular disease independent of traditional risk factors. 36 Moreover, when we examined which variables including carotid artery SUV, venous blood SUV, and TBR value were independently associated with %FMD, TBR value was the strongest correlate of decreased %FMD (β=−2.506; P=0.002). Carotid artery SUV (β=0.295; P<0.001), %FMD (β=0.017; P<0.001), and prevalence of coronary artery disease (β=−0.125; P=0.016) were independently correlated with blood pool SUV. These findings suggest that blood signal was correlated with %FMD, but normalization of arterial wall signal by the blood pool was effective in controlling for the partial volume effects. Therefore, although the partial volume effects might interfere with signal quantification of FDG uptake in the thin carotid arteries because of the limited resolution of the PET imaging, carotid artery TBR values in the FDG-PET imaging could be a reliable marker for vascular inflammation within the carotid atherosclerosis. Higher resolution PET systems and development of novel tracers for the detection of arterial inflammation will overcome the current methodological limitations of FDG-PET imaging.
Limitations
Our study had several limitations. First, we measured endothelial function and vascular inflammation at different vascular regions; the former was evaluated at brachial artery, and the latter at carotid arteries. The subject population enrolled was relatively low risk; therefore, the generalizability of the study was limited by the exclusion of individuals with uncontrolled diabetes mellitus. Second, we did not know why statin use was not associated with either TBR values or %FMD in the study design 1. It may be because of a lack of statistical power. Another reason why statin therapy was not correlated with either change in TBR values (P=0.495) or %FMD (P=0.061) in the study design 2 may be that statins could not affect the effects of antihypertensive agents on endothelial function or vascular inflammation. Third, although univariate regression analysis revealed no significant correlation between various medication and vascular inflammation or %FMD, we cannot totally exclude the possibility that other medication could affect the present results because both endothelial function and vascular inflammation may be influenced by numerous therapeutic agents. However, it was unlikely that effects of antihypertensive medication on renal function could confound the present findings. Fourth, the treatment substudy had several limitations; there was a relatively small reduction (5.3%) in vascular inflammation after 6-month antihypertensive treatment, and we had no control group in the study design 2. Nonetheless, antihypertensive therapy significantly improved endothelial function evaluated by %FMD (from 5.94±1.70 to 6.73±1.60; P<0.001) and suppressed vascular inflammation measured by carotid artery TBR (from 1.51±0.24 to 1.43±0.20; P=0.007), and reduction of carotid artery TBR was a sole independent predictor of improvement of %FMD after 6-month antihypertensive treatment (Table 4 ). In addition, temporal blinding was used in the analysis. So the present findings suggest the association of vascular inflammation with endothelial dysfunction in humans. Fifth, the association between %FMD and TBR does not necessarily imply biological causation. The relationship could be in the opposite direction (endothelial dysfunction may predispose to arterial inflammation) or alas the 2 factors could be separately related to yet another unaccounted factor. Accordingly, further longitudinal studies are needed to clarify whether the suppression of arterial inflammation assessed by carotid artery TBR might reduce the risk of future cardiovascular events in humans.
Conclusions
We demonstrated that vascular inflammation in the carotid arteries evaluated by FDG-PET was one of the independent correlates of decreased %FMD and that there was an inverse correlation between ∆TBR and ∆%FMD in hypertensive patients, thus suggesting the association of vascular inflammation with endothelial dysfunction in humans. Log-transformed value was used. ADMA indicates asymmetrical dimethyl arginine; HDL, high-density lipoprotein; homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; low-density lipoprotein; and TBR, target:background ratio.
*Indicates statistically significant. †Log-transformed value was used.
